

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Huakang Biomedical Holdings Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to announce that Ms. Shih Mei Ling (施美伶, with a former Chinese name of 施美玲) ("**Ms. Shih**") has been appointed as an independent non-executive director of the Company ("**INED**") with effect from 3 December 2024.

Ms. Shih, aged 43, has more than 18 years of experience working in licensed corporations regulated under Securities and Futures Commission in dealing in securities and futures contracts, advising on securities and asset management. Ms. Shih is currently a licensed person registered under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) ("**SFO**") to carry out Type 1 (dealing in securities), Type 4 (advising on securities) and Type 9 (asset management) regulated activities. Since March 2023, Ms. Shih has served as a director and responsible officer in Type 1 (dealing in securities) regulated activities in Hang Tai Securities Limited ("**Hang Tai Securities**"), a licensed corporation registered under the SFO. In addition, from August 2024, Ms. Shih has also served as a responsible officer in Type 4 (advising on securities) and Type 9 (asset management) regulated activities in Hang Tai Asset Management Limited, a licensed corporation registered under the SFO.

Ms. Shih joined Vantum Futures Limited, a licensed corporation under the SFO, as a licensed representative for Type 2 (dealing in futures contracts) from March 2023 to April 2023. She then served as a responsible officer at Vantum Futures Limited for Type 2 (dealing in futures contracts) from April 2023 to October 2023.

From February 2023 to March 2023, she was a licensed representative at Hang Tai Securities for Type 1 (dealing in securities) regulated activities. She joined Sino Capital Securities Limited, a licensed corporation under the SFO, as a licensed representative for Type 1 (dealing in securities) in October 2022. She then served as a responsible officer at Sino Capital Securities Limited for Type 1 (dealing in securities) regulated activities from October 2022 to January 2023.

Additionally, Ms. Shih served as a licensed representative at KGI Asia Limited, a licensed corporation under the SFO, for Type 1 (dealing in securities) regulated activities from September 2006 to September 2022, and for Type 4 (advising on securities) regulated activities from March 2008 to September 2022. She also worked as a licensed representative at KGI Futures (Hong Kong) Limited, a licensed corporation under the SFO, from September 2006 to September 2022 for Type 2 (dealing in futures contracts) regulated activities.

Ms. Shih was a director of Greenwalker Asia Limited (“**Greenwalker Asia**”) and JS Capital Limited (“**JS Capital**”), which were companies incorporated in Hong Kong and were dissolved by deregistration on 13 April 2017 and 28 September 2012 respectively. Ms. Shih was a director of each of Greenwalker Asia and JS Capital when each such company was dissolved. Greenwalker Asia and JS Capital were engaged in marketing and trading business respectively. As confirmed by Ms. Shih all such companies had ceased operation before dissolution, and each company was solvent at the time when it was dissolved. The dissolution of these companies has not resulted in any obligations or liabilities against Ms. Shih.

Ms. Shih graduated from the University of Portsmouth in the United Kingdom in April 2008 with an honours degree in Bachelor of Arts in Business Administration.

Ms. Shih has entered into an appointment letter with the Company for an initial term of three years commencing from 3 December 2024 and will continue thereafter until terminated by either party serving not less than one month’s written notice to the other party. Pursuant to the appointment letter, Ms. Shih is entitled to a director’s emolument of HK\$100,000 per annum. Such fee is determined by the Board based on the recommendation of the remuneration committee with reference to her experience, responsibilities, workload and time devoted to the Company and will be subject to review by the remuneration committee of the Company from time to time. Save as disclosed above, Ms. Shih is not expected to receive any other remuneration for holding her office as an INED.

In accordance with the articles of association of the Company, Ms. Shih will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election. Ms. Shih will be subject to rotation requirements as contained in the articles of association of the Company and shall retire from office by rotation at least once every three years.

Ms. Shih confirmed that (i) she meets the independence criteria as set out in Rule 5.09 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (“**GEM Listing Rules**”); (ii) she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the GEM Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, as at the date of this announcement, Ms. Shih (i) does not hold any other position in the Company and other members of the Group; (ii) did not hold any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iii) does not possess any other major appointments or professional qualifications; (iv) does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company; and (v) does not have any interests in the shares of the Company or any of its associated corporations which is required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any information which is disclosable nor is/was Ms. Shih involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters concerning Ms. Shih that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Ms. Shih for joining the Board.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 3 December 2024

As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; the Non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary, Ms. Chow Ching Man and Ms. Shih Mei Ling.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.